In the latest trading session, 0.98 million Compass Therapeutics Inc (NASDAQ:CMPX) shares changed hands as the company’s beta touched 0.71. With the company’s most recent per share price at $1.99 changing hands around $0.22 or 12.43% at last look, the market valuation stands at $273.80M. CMPX’s current price is a discount, trading about -34.67% off its 52-week high of $2.68. The share price had its 52-week low at $0.76, which suggests the last value was 61.81% up since then. When we look at Compass Therapeutics Inc’s average trading volume, we note the 10-day average is 3.0 million shares, with the 3-month average coming to 898.11K.
Analysts gave the Compass Therapeutics Inc (CMPX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.38. If we narrow down to specifics, the data shows that 1 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CMPX as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Compass Therapeutics Inc’s EPS for the current quarter is expected to be -0.09.
Compass Therapeutics Inc (NASDAQ:CMPX) trade information
Instantly CMPX is in green as seen in intraday trades today. With action 27.56%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 37.24%, with the 5-day performance at 27.56% in the green. However, in the 30-day time frame, Compass Therapeutics Inc (NASDAQ:CMPX) is 11.80% up. Looking at the short shares, we see there were 2.1 million shares sold at short interest cover period of 4.14 days.
The consensus price target for the stock as assigned by Wall Street analysts is 5, meaning bulls need an upside of 60.2% from its recent market value. According to analyst projections, CMPX’s forecast low is 5 with 5 as the target high. To hit the forecast high, the stock’s price needs a -151.26% plunge from its current level, while the stock would need to soar -151.26% for it to hit the projected low.
Compass Therapeutics Inc (CMPX) estimates and forecasts
Data shows that the Compass Therapeutics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 84.26% over the past 6 months, a -6.06% in annual growth rate that is considerably lower than the industry average of 16.40%.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 12.88%. The 2025 estimates are for Compass Therapeutics Inc earnings to decrease by -6.06%.
CMPX Dividends
Compass Therapeutics Inc is expected to release its next quarterly earnings report in February.
Compass Therapeutics Inc (NASDAQ:CMPX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 12.55% of Compass Therapeutics Inc shares while 69.16% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 79.09%. There are 69.16% institutions holding the Compass Therapeutics Inc stock share, with ORBIMED ADVISORS LLC the top institutional holder. As of 2024-06-30, the company held 16.3701% of the shares, roughly 22.36 million CMPX shares worth $22.36 million.
ADAGE CAPITAL PARTNERS GP, L.L.C. holds the second largest percentage of outstanding shares, with 8.1474% or 11.13 million shares worth $11.13 million as of 2024-06-30.
Among Mutual Funds, the top two as of Oct 31, 2024 were iShares Russell 2000 ETF and Vanguard Total Stock Market Index Fund. With 2.52 shares estimated at $4.98 million under it, the former controlled 4.83% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 4.20% of the shares, roughly 2.19 shares worth around $4.34 million.
